You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameParecoxib
Accession NumberDB08439
TypeSmall Molecule
GroupsApproved
DescriptionParecoxib is a water-soluble and injectable prodrug of valdecoxib. It is marketed as Dynastat in the European Union. Parecoxib is a COX2 selective inhibitor in the same category as celecoxib (Celebrex) and rofecoxib (Vioxx). As it is injectable, it can be used perioperatively when patients are unable to take oral medications. It is approved through much of Europe for short term perioperative pain control much in the same way ketorolac (Toradol) is used in the United States. In 2005, the U.S. Food and Drug Administration (FDA) issued a letter of non-approval for parecoxib in the United States.
Structure
Thumb
SynonymsNot Available
External Identifiers
  • SC 69124
  • SC-69124
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DynastatNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII9TUW81Y3CE
CAS number198470-84-7
WeightAverage: 370.422
Monoisotopic: 370.098727764
Chemical FormulaC19H18N2O4S
InChI KeyTZRHLKRLEZJVIJ-UHFFFAOYSA-N
InChI
InChI=1S/C19H18N2O4S/c1-3-17(22)21-26(23,24)16-11-9-14(10-12-16)18-13(2)25-20-19(18)15-7-5-4-6-8-15/h4-12H,3H2,1-2H3,(H,21,22)
IUPAC Name
N-[4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonyl]propanamide
SMILES
CCC(=O)NS(=O)(=O)C1=CC=C(C=C1)C1=C(C)ON=C1C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzenesulfonamides
Direct ParentBenzenesulfonamides
Alternative Parents
Substituents
  • Benzenesulfonamide
  • Heteroaromatic compound
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Oxazole
  • Isoxazole
  • Azole
  • Carboxamide group
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationUsed for short term perioperative pain control.
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding98%
Metabolism

Hepatic. Metabolized primarily via CYP3A4 and 2C9 to valdecoxib and propionic acid.

Route of eliminationNot Available
Half life22 minutes (parecoxib); 8 hours (valdecoxib)
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.8694
Caco-2 permeable-0.644
P-glycoprotein substrateNon-substrate0.8144
P-glycoprotein inhibitor INon-inhibitor0.7995
P-glycoprotein inhibitor IINon-inhibitor0.8537
Renal organic cation transporterNon-inhibitor0.8889
CYP450 2C9 substrateNon-substrate0.702
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateNon-substrate0.6159
CYP450 1A2 substrateNon-inhibitor0.8459
CYP450 2C9 inhibitorInhibitor0.801
CYP450 2D6 inhibitorNon-inhibitor0.8356
CYP450 2C19 inhibitorInhibitor0.6608
CYP450 3A4 inhibitorNon-inhibitor0.5165
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8722
Ames testNon AMES toxic0.7504
CarcinogenicityCarcinogens 0.5086
BiodegradationNot ready biodegradable0.9899
Rat acute toxicity2.2665 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9874
hERG inhibition (predictor II)Non-inhibitor0.9083
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0162 mg/mLALOGPS
logP3.42ALOGPS
logP3.51ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)4.24ChemAxon
pKa (Strongest Basic)0.42ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area89.27 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity98.9 m3·mol-1ChemAxon
Polarizability38 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesM01AH04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AbciximabParecoxib may increase the anticoagulant activities of Abciximab.
AbirateroneThe metabolism of Parecoxib can be decreased when combined with Abiraterone.
AcebutololParecoxib may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Parecoxib.
AcenocoumarolParecoxib may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Parecoxib.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Parecoxib.
Alendronic acidThe risk or severity of adverse effects can be increased when Parecoxib is combined with Alendronic acid.
AliskirenParecoxib may decrease the antihypertensive activities of Aliskiren.
AlprenololParecoxib may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Parecoxib.
AmikacinParecoxib may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideParecoxib may decrease the antihypertensive activities of Amiloride.
AmiodaroneThe serum concentration of Parecoxib can be increased when it is combined with Amiodarone.
AncrodParecoxib may increase the anticoagulant activities of Ancrod.
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Parecoxib.
Antithrombin III humanParecoxib may increase the anticoagulant activities of Antithrombin III human.
ApixabanParecoxib may increase the anticoagulant activities of Apixaban.
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Parecoxib.
AprepitantThe serum concentration of Parecoxib can be increased when it is combined with Aprepitant.
ArdeparinParecoxib may increase the anticoagulant activities of Ardeparin.
ArgatrobanParecoxib may increase the anticoagulant activities of Argatroban.
ArotinololParecoxib may decrease the antihypertensive activities of Arotinolol.
AtazanavirThe serum concentration of Parecoxib can be increased when it is combined with Atazanavir.
AtenololParecoxib may decrease the antihypertensive activities of Atenolol.
AtomoxetineThe metabolism of Parecoxib can be decreased when combined with Atomoxetine.
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Parecoxib.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Parecoxib.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Parecoxib.
BalsalazideParecoxib may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Parecoxib.
BecaplerminParecoxib may increase the anticoagulant activities of Becaplermin.
BefunololParecoxib may decrease the antihypertensive activities of Befunolol.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Parecoxib.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Parecoxib.
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Parecoxib.
BetaxololParecoxib may decrease the antihypertensive activities of Betaxolol.
BevantololParecoxib may decrease the antihypertensive activities of Bevantolol.
BexaroteneThe serum concentration of Parecoxib can be decreased when it is combined with Bexarotene.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Parecoxib.
BisoprololParecoxib may decrease the antihypertensive activities of Bisoprolol.
BivalirudinParecoxib may increase the anticoagulant activities of Bivalirudin.
BoceprevirThe serum concentration of Parecoxib can be increased when it is combined with Boceprevir.
BopindololParecoxib may decrease the antihypertensive activities of Bopindolol.
BortezomibThe metabolism of Parecoxib can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Parecoxib can be decreased when it is combined with Bosentan.
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Parecoxib.
BufuralolParecoxib may decrease the antihypertensive activities of Bufuralol.
BumetanideParecoxib may decrease the diuretic activities of Bumetanide.
BupranololParecoxib may decrease the antihypertensive activities of Bupranolol.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Parecoxib.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Parecoxib.
CapecitabineThe serum concentration of Parecoxib can be increased when it is combined with Capecitabine.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Parecoxib.
CarbamazepineThe metabolism of Parecoxib can be increased when combined with Carbamazepine.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Parecoxib.
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Parecoxib.
CarteololParecoxib may decrease the antihypertensive activities of Carteolol.
CarvedilolParecoxib may decrease the antihypertensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Parecoxib.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Parecoxib.
CeliprololParecoxib may decrease the antihypertensive activities of Celiprolol.
CeritinibThe serum concentration of Parecoxib can be increased when it is combined with Ceritinib.
CertoparinParecoxib may increase the anticoagulant activities of Certoparin.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Parecoxib.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Parecoxib.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Parecoxib.
CholecalciferolThe metabolism of Parecoxib can be decreased when combined with Cholecalciferol.
CholestyramineCholestyramine can cause a decrease in the absorption of Parecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Parecoxib.
Citric AcidParecoxib may increase the anticoagulant activities of Citric Acid.
ClarithromycinThe serum concentration of Parecoxib can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Parecoxib can be decreased when combined with Clemastine.
ClodronateThe risk or severity of adverse effects can be increased when Parecoxib is combined with Clodronate.
ClonixinThe risk or severity of adverse effects can be increased when Parecoxib is combined with Clonixin.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Parecoxib.
ClotrimazoleThe metabolism of Parecoxib can be decreased when combined with Clotrimazole.
CobicistatThe serum concentration of Parecoxib can be increased when it is combined with Cobicistat.
ColesevelamColesevelam can cause a decrease in the absorption of Parecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Parecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.
ConivaptanThe serum concentration of Parecoxib can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Parecoxib can be decreased when combined with Crizotinib.
CyclosporineParecoxib may increase the nephrotoxic activities of Cyclosporine.
CyclosporineThe metabolism of Parecoxib can be decreased when combined with Cyclosporine.
D-LimoneneThe risk or severity of adverse effects can be increased when Parecoxib is combined with D-Limonene.
Dabigatran etexilateParecoxib may increase the anticoagulant activities of Dabigatran etexilate.
DabrafenibThe serum concentration of Parecoxib can be decreased when it is combined with Dabrafenib.
DalteparinParecoxib may increase the anticoagulant activities of Dalteparin.
DanaparoidParecoxib may increase the anticoagulant activities of Danaparoid.
DarunavirThe serum concentration of Parecoxib can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Parecoxib can be increased when it is combined with Dasatinib.
DaunorubicinParecoxib may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DeferasiroxThe serum concentration of Parecoxib can be decreased when it is combined with Deferasirox.
DeferasiroxThe risk or severity of adverse effects can be increased when Parecoxib is combined with Deferasirox.
DelavirdineThe serum concentration of Parecoxib can be increased when it is combined with Delavirdine.
DesirudinParecoxib may increase the anticoagulant activities of Desirudin.
DesmopressinThe risk or severity of adverse effects can be increased when Parecoxib is combined with Desmopressin.
DexamethasoneThe serum concentration of Parecoxib can be decreased when it is combined with Dexamethasone.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Parecoxib.
DextranParecoxib may increase the anticoagulant activities of Dextran.
Dextran 40Parecoxib may increase the anticoagulant activities of Dextran 40.
Dextran 70Parecoxib may increase the anticoagulant activities of Dextran 70.
Dextran 75Parecoxib may increase the anticoagulant activities of Dextran 75.
DextromethorphanThe serum concentration of Dextromethorphan can be increased when it is combined with Parecoxib.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Parecoxib.
DicoumarolParecoxib may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Parecoxib.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Parecoxib.
DihydroergotamineThe metabolism of Parecoxib can be decreased when combined with Dihydroergotamine.
DihydrostreptomycinParecoxib may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DiltiazemThe metabolism of Parecoxib can be decreased when combined with Diltiazem.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Parecoxib.
DoxorubicinParecoxib may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DoxycyclineThe metabolism of Parecoxib can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Parecoxib can be decreased when combined with Dronedarone.
DrospirenoneParecoxib may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Parecoxib is combined with Droxicam.
Edetic AcidParecoxib may increase the anticoagulant activities of Edetic Acid.
EdoxabanParecoxib may increase the anticoagulant activities of Edoxaban.
EfavirenzThe serum concentration of Parecoxib can be decreased when it is combined with Efavirenz.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Parecoxib.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Parecoxib.
EnoxaparinParecoxib may increase the anticoagulant activities of Enoxaparin.
EnzalutamideThe serum concentration of Parecoxib can be decreased when it is combined with Enzalutamide.
EpirizoleThe risk or severity of adverse effects can be increased when Parecoxib is combined with Epirizole.
EpirubicinParecoxib may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneParecoxib may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Parecoxib.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Parecoxib.
ErythromycinThe metabolism of Parecoxib can be decreased when combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Parecoxib can be decreased when it is combined with Eslicarbazepine acetate.
EsmololParecoxib may decrease the antihypertensive activities of Esmolol.
Etacrynic acidParecoxib may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Parecoxib.
Ethyl biscoumacetateParecoxib may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when Parecoxib is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Parecoxib.
EtofenamateThe risk or severity of adverse effects can be increased when Parecoxib is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Parecoxib.
EtravirineThe serum concentration of Parecoxib can be decreased when it is combined with Etravirine.
Evening primrose oilThe risk or severity of adverse effects can be increased when Parecoxib is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Parecoxib.
FenbufenThe risk or severity of adverse effects can be increased when Parecoxib is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Parecoxib.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Parecoxib.
FloxuridineThe serum concentration of Parecoxib can be increased when it is combined with Floxuridine.
FluconazoleThe serum concentration of Parecoxib can be increased when it is combined with Fluconazole.
FlunixinThe risk or severity of adverse effects can be increased when Parecoxib is combined with Flunixin.
FluorouracilThe serum concentration of Parecoxib can be increased when it is combined with Fluorouracil.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Parecoxib.
FluvastatinThe metabolism of Parecoxib can be decreased when combined with Fluvastatin.
FluvoxamineThe metabolism of Parecoxib can be decreased when combined with Fluvoxamine.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Parecoxib.
Fondaparinux sodiumParecoxib may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Parecoxib.
FosamprenavirThe metabolism of Parecoxib can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Parecoxib can be increased when it is combined with Fosaprepitant.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Parecoxib.
FosphenytoinThe metabolism of Parecoxib can be increased when combined with Fosphenytoin.
FramycetinParecoxib may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideParecoxib may decrease the diuretic activities of Furosemide.
Fusidic AcidThe serum concentration of Parecoxib can be increased when it is combined with Fusidic Acid.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Parecoxib.
GemfibrozilThe serum concentration of Parecoxib can be increased when it is combined with Gemfibrozil.
GentamicinParecoxib may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
HaloperidolThe risk or severity of adverse effects can be increased when Parecoxib is combined with Haloperidol.
HeparinParecoxib may increase the anticoagulant activities of Heparin.
HirulogParecoxib may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Parecoxib.
HydralazineParecoxib may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Parecoxib.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Parecoxib.
Hygromycin BParecoxib may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Parecoxib is combined with Ibandronate.
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Parecoxib.
IbuproxamThe risk or severity of adverse effects can be increased when Parecoxib is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Parecoxib.
IdarubicinParecoxib may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IdelalisibThe serum concentration of Parecoxib can be increased when it is combined with Idelalisib.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Parecoxib.
ImatinibThe metabolism of Parecoxib can be decreased when combined with Imatinib.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Parecoxib.
IndenololParecoxib may decrease the antihypertensive activities of Indenolol.
IndinavirThe serum concentration of Parecoxib can be increased when it is combined with Indinavir.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Parecoxib.
IndoprofenThe risk or severity of adverse effects can be increased when Parecoxib is combined with Indoprofen.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Parecoxib.
IsavuconazoniumThe metabolism of Parecoxib can be decreased when combined with Isavuconazonium.
IsoxicamThe risk or severity of adverse effects can be increased when Parecoxib is combined with Isoxicam.
IsradipineThe metabolism of Parecoxib can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Parecoxib can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Parecoxib can be increased when it is combined with Ivacaftor.
KanamycinParecoxib may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when Parecoxib is combined with Kebuzone.
KetoconazoleThe serum concentration of Parecoxib can be increased when it is combined with Ketoconazole.
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Parecoxib.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Parecoxib.
LabetalolParecoxib may decrease the antihypertensive activities of Labetalol.
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Parecoxib.
LepirudinParecoxib may increase the anticoagulant activities of Lepirudin.
LevobunololParecoxib may decrease the antihypertensive activities of Levobunolol.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Parecoxib.
LithiumThe serum concentration of Lithium can be increased when it is combined with Parecoxib.
LopinavirThe serum concentration of Parecoxib can be increased when it is combined with Lopinavir.
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Parecoxib.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Parecoxib.
LovastatinThe metabolism of Parecoxib can be decreased when combined with Lovastatin.
LoxoprofenThe risk or severity of adverse effects can be increased when Parecoxib is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Parecoxib.
LuliconazoleThe serum concentration of Parecoxib can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Parecoxib can be decreased when it is combined with Lumacaftor.
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Parecoxib.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Parecoxib.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Parecoxib.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Parecoxib.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Parecoxib.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Parecoxib.
MesalazineParecoxib may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Parecoxib.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Parecoxib.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Parecoxib.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Parecoxib.
MetipranololParecoxib may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Parecoxib.
MetoprololParecoxib may decrease the antihypertensive activities of Metoprolol.
MetrizamideParecoxib may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MifepristoneThe metabolism of Parecoxib can be decreased when combined with Mifepristone.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Parecoxib.
MitotaneThe serum concentration of Parecoxib can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Parecoxib can be decreased when it is combined with Modafinil.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Parecoxib.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Parecoxib.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Parecoxib.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Parecoxib.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Parecoxib.
NadololParecoxib may decrease the antihypertensive activities of Nadolol.
NadroparinParecoxib may increase the anticoagulant activities of Nadroparin.
NafcillinThe serum concentration of Parecoxib can be decreased when it is combined with Nafcillin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Parecoxib.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Parecoxib.
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Parecoxib.
NefazodoneThe serum concentration of Parecoxib can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Parecoxib can be increased when it is combined with Nelfinavir.
NeomycinParecoxib may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Parecoxib.
NetilmicinParecoxib may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
NetupitantThe serum concentration of Parecoxib can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Parecoxib can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Parecoxib can be increased when it is combined with Nicardipine.
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Parecoxib.
NilotinibThe metabolism of Parecoxib can be decreased when combined with Nilotinib.
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Parecoxib.
OlaparibThe metabolism of Parecoxib can be decreased when combined with Olaparib.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Parecoxib.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Parecoxib.
OlsalazineParecoxib may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Parecoxib.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Parecoxib is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Parecoxib.
OmeprazoleThe metabolism of Parecoxib can be decreased when combined with Omeprazole.
OrgoteinThe risk or severity of adverse effects can be increased when Parecoxib is combined with Orgotein.
OsimertinibThe serum concentration of Parecoxib can be increased when it is combined with Osimertinib.
OtamixabanParecoxib may increase the anticoagulant activities of Otamixaban.
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Parecoxib.
OxprenololParecoxib may decrease the antihypertensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Parecoxib.
PalbociclibThe serum concentration of Parecoxib can be increased when it is combined with Palbociclib.
PamidronateThe risk or severity of adverse effects can be increased when Parecoxib is combined with Pamidronate.
ParomomycinParecoxib may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PenbutololParecoxib may decrease the antihypertensive activities of Penbutolol.
PentobarbitalThe metabolism of Parecoxib can be increased when combined with Pentobarbital.
Pentosan PolysulfateParecoxib may increase the anticoagulant activities of Pentosan Polysulfate.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Parecoxib.
PhenindioneParecoxib may increase the anticoagulant activities of Phenindione.
PhenobarbitalThe metabolism of Parecoxib can be increased when combined with Phenobarbital.
PhenprocoumonParecoxib may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Parecoxib.
PhenytoinThe metabolism of Parecoxib can be increased when combined with Phenytoin.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Parecoxib.
PindololParecoxib may decrease the antihypertensive activities of Pindolol.
PiretanideParecoxib may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Parecoxib.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Parecoxib.
PlicamycinParecoxib may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Parecoxib.
PosaconazoleThe serum concentration of Parecoxib can be increased when it is combined with Posaconazole.
PractololParecoxib may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Parecoxib.
PrimidoneThe metabolism of Parecoxib can be increased when combined with Primidone.
ProbenecidThe serum concentration of Parecoxib can be increased when it is combined with Probenecid.
PropacetamolThe risk or severity of adverse effects can be increased when Parecoxib is combined with Propacetamol.
PropranololParecoxib may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Parecoxib.
Protein CParecoxib may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeParecoxib may increase the anticoagulant activities of Protocatechualdehyde.
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Parecoxib.
PuromycinParecoxib may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
PyrimethamineThe metabolism of Parecoxib can be decreased when combined with Pyrimethamine.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Parecoxib.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Parecoxib.
QuinineThe metabolism of Parecoxib can be decreased when combined with Quinine.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Parecoxib.
RanolazineThe metabolism of Parecoxib can be decreased when combined with Ranolazine.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Parecoxib.
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Parecoxib.
ReviparinParecoxib may increase the anticoagulant activities of Reviparin.
RibostamycinParecoxib may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RifabutinThe metabolism of Parecoxib can be increased when combined with Rifabutin.
RifampicinThe metabolism of Parecoxib can be increased when combined with Rifampicin.
RifapentineThe metabolism of Parecoxib can be increased when combined with Rifapentine.
RisedronateThe risk or severity of adverse effects can be increased when Parecoxib is combined with Risedronate.
RitonavirThe serum concentration of Parecoxib can be increased when it is combined with Ritonavir.
RivaroxabanParecoxib may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Parecoxib.
SalicylamideThe risk or severity of adverse effects can be increased when Parecoxib is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Parecoxib.
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Parecoxib.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Parecoxib.
SaquinavirThe serum concentration of Parecoxib can be increased when it is combined with Saquinavir.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Parecoxib.
SecobarbitalThe metabolism of Parecoxib can be increased when combined with Secobarbital.
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Parecoxib.
SildenafilThe metabolism of Parecoxib can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Parecoxib can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Parecoxib can be increased when it is combined with Simeprevir.
SorafenibThe metabolism of Parecoxib can be decreased when combined with Sorafenib.
SotalolParecoxib may decrease the antihypertensive activities of Sotalol.
SpectinomycinParecoxib may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Parecoxib.
SpironolactoneParecoxib may decrease the antihypertensive activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Parecoxib.
St. John's WortThe serum concentration of Parecoxib can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Parecoxib can be increased when it is combined with Stiripentol.
StreptomycinParecoxib may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinParecoxib may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulfadiazineThe serum concentration of Parecoxib can be increased when it is combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Parecoxib can be decreased when combined with Sulfamethoxazole.
SulfasalazineParecoxib may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Parecoxib.
SulfisoxazoleThe serum concentration of Parecoxib can be increased when it is combined with Sulfisoxazole.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Parecoxib.
SulodexideParecoxib may increase the anticoagulant activities of Sulodexide.
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Parecoxib.
TacrolimusParecoxib may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Parecoxib.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Parecoxib.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Parecoxib is combined with Technetium Tc-99m Medronate.
TelaprevirThe serum concentration of Parecoxib can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Parecoxib can be increased when it is combined with Telithromycin.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Parecoxib.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Parecoxib.
TenofovirThe risk or severity of adverse effects can be increased when Parecoxib is combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Parecoxib.
TepoxalinThe risk or severity of adverse effects can be increased when Parecoxib is combined with Tepoxalin.
TeriflunomideThe risk or severity of adverse effects can be increased when Parecoxib is combined with Teriflunomide.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Parecoxib.
TicagrelorThe metabolism of Parecoxib can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Parecoxib can be decreased when combined with Ticlopidine.
TiludronateThe risk or severity of adverse effects can be increased when Parecoxib is combined with Tiludronate.
TimololParecoxib may decrease the antihypertensive activities of Timolol.
TobramycinParecoxib may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
TocilizumabThe serum concentration of Parecoxib can be decreased when it is combined with Tocilizumab.
TolbutamideThe serum concentration of Parecoxib can be increased when it is combined with Tolbutamide.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Parecoxib is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Parecoxib.
TorasemideParecoxib may decrease the diuretic activities of Torasemide.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Parecoxib.
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Parecoxib.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Parecoxib.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Parecoxib.
TriamtereneParecoxib may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Parecoxib.
TrimethoprimThe metabolism of Parecoxib can be decreased when combined with Trimethoprim.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Parecoxib.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Parecoxib.
Valproic AcidThe metabolism of Parecoxib can be decreased when combined with Valproic Acid.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Parecoxib.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Parecoxib.
VenlafaxineThe metabolism of Parecoxib can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Parecoxib can be decreased when combined with Verapamil.
VoriconazoleThe serum concentration of Parecoxib can be increased when it is combined with Voriconazole.
WarfarinParecoxib may increase the anticoagulant activities of Warfarin.
XimelagatranParecoxib may increase the anticoagulant activities of Ximelagatran.
ZafirlukastThe metabolism of Parecoxib can be decreased when combined with Zafirlukast.
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Parecoxib.
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Parecoxib.
ZiprasidoneThe metabolism of Parecoxib can be decreased when combined with Ziprasidone.
Zoledronic acidThe risk or severity of adverse effects can be increased when Parecoxib is combined with Zoledronic acid.
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Parecoxib.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Talley JJ, Bertenshaw SR, Brown DL, Carter JS, Graneto MJ, Kellogg MS, Koboldt CM, Yuan J, Zhang YY, Seibert K: N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration. J Med Chem. 2000 May 4;43(9):1661-3. [PubMed:10794682 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serine-type endopeptidase activity
Specific Function:
Transferrins are iron binding transport proteins which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate.Lactotransferrin is a major iron-binding and multifunctional protein found in exocrine fluids such as breast milk and mucosal secretions. Has antimicrobial activity, which depends on the extracellular cation concentration. Antimicrobial properties incl...
Gene Name:
LTF
Uniprot ID:
P02788
Molecular Weight:
78181.225 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Ibrahim AE, Feldman J, Karim A, Kharasch ED: Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. Anesthesiology. 2003 Apr;98(4):853-61. [PubMed:12657846 ]
  2. DrugBank Entry Valdecoxib (is a prodrug of Valdecoxib) [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. DrugBank Entry Valdecoxib (is a prodrug of Valdecoxib) [Link]
Comments
comments powered by Disqus
Drug created on September 15, 2010 15:31 / Updated on August 17, 2016 12:24